ClinicalTrials.gg
Status unknownNCT02987075Updated Jul 17, 2017

A Comparison of Ongoing Pregnancy Rate Between Cleavage Stage and Early Compacting Embryo Transfer at 66±2 Hours After ICSI Using Single Step Culture Medium

An interventional study of Compacting embryo transferring and Non- compacting embryo transferring in Infertility, sponsored by Vietnam National University. Status unknown at 1 site in Vietnam. Open to female participants. Per ClinicalTrials.gov, last updated 2017-07-17.

Sponsored by Vietnam National University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
430
Allocation
Randomized
Sex
Female
01

Study summary

A comparison of ongoing pregnancy rate between cleavage stage and early compacting embryo transfer at 66±2 hours after ICSI using single step culture medium

Read the detailed description

A prospective cohort study to compare the outcomes of transferring the early compacting and the cleavage day 3 embryos.

All participants were treated with a gonadotropin-releasing antagonist protocol according to local protocol. Recombinant follicle stimulating hormone was given for five days starting on the second or third day of the menstrual cycle at a starting dose individualized for each participant as follows: 150, 225 or 300 IU/day, respectively, in participants with anti-Müllerian hormone levels of \<2.1 ng/mL, 0.7-2.1 ng/mL or \<0.7 ng/mL. This dosage could then be titrated based on clinical judgement of the investigator. Follicular development was monitored using ultrasound scanning and measurement of estradiol and progesterone levels, starting on day five of stimulation; scanning and hormonal measurements were repeated every two to three days, depending on follicle size. An antagonist was routinely used on day five until the day of human chorionic gonadotropin administration. Criteria for administration of recombinant human chorionic gonadotropin (5,000 IU) was the presence of at least two leading follicles of 17 mm in diameter. Oocyte retrieval was performed 36 hours after recombinant human chorionic gonadotropin administration.

Insemination was performed using intra-cytoplasmic sperm injection at three to four hours after oocyte retrieval; only matured oocytes were inseminated. Fertilization check was performed under inverted microscope at 16-18 hours after insemination. Embryo evaluation was performed on day 3 at fixed time point after fertilization (66±2 hours) using the Istanbul consensus. As a rule, two useful embryos are transferred in patients if having either early compaction or still on cleavage stage.

Early compaction embryo transfer group: transfer of 2 utilizable compacting embryos.

Cleavage stage embryo transfer group: transfer of 2 utilizable non-compacting embryos have 7-9 cells with under 20% fragmentation.

Embryo transfer was performed using a soft catheter by a standard technique under ultrasound guidance. Intensive luteal phase support was provided using progesterone gel and estradiol. At least 18 days after OPU, a urinary pregnancy test is performed. If the pregnancy test is positive, vaginal and/or abdominal ultrasonographic investigation is performed between 35 and 42 days (5 to 6 weeks) after ET to confirm a clinical pregnancy and at least 70 days (≥10 weeks) after ET to confirm an ongoing pregnancy.

Other clinical parameters will also be evaluated: serum hormone levels, fertilization rate, number and quality of day 3 embryos, implantation rate, ectopic pregnancy rate and miscarriage rate.

02

Conditions studied

  • Infertility

Browse trials for

03

In context

Infertility

2,085 studies on the registry are indexed under Infertility; 357 are open to participants now.

This study's planned enrollment of 430 is above the median of 135 across 1,412 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Vietnam National University is the lead sponsor of 16 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • IVF treatment for infertility
  • Controlled ovarian hyperstimulation by GnRH antagonist protocol.
  • IVF cycles ≤2
  • Eligible for transfer of 2 embryos on day 3
  • Have at least 2 embryos which are 7-9 cells and fragmentation ≤20%, that had either early compaction or still on cleavage stage

Exclusion criteria

Exclusion Criteria:

  • Oocyte donation cycles
  • Abnormal uterine
  • Using GnRH agonist for triggering.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
430 participants (estimated)

Study arms

  • Other
    Early compaction embryo group

    patients have compacting embryos at 66±2 hours after ICSI

    Other: Compacting embryo transferring

  • Other
    Cleavage stage embryo group

    patients have non-compacting embryos with 7-9 cells, under 20% fragmentation. at 66±2 hours after ICSI

    Other: Non- compacting embryo transferring

Interventions

  • OtherCompacting embryo transferring

    transfer of 2 utilizable compacting embryos

  • OtherNon- compacting embryo transferring

    transfer of 2 utilizable non-compacting embryos have 7-9 cells with under 20% fragmentation.

06

What researchers measure

Primary outcomes

  1. The primary outcome measure was ongoing pregnancy rate, defined as a pregnancy with a detectable heart rate at 12 weeks of gestation or beyond.

    Time frame: 12 weeks

Secondary outcomes

  1. Clinical pregnancy rate, defined as the presence of a gestational sac under ultrasonography

    Time frame: 7 weeks

  2. Implantation rate (number of gestational sacs on ultrasound at 7 weeks / total number of embryos transferred x 100).

    Time frame: 7 weeks

  3. Ectopic pregnancy rate, defined as the ectopic nidation of a pregnancy, confirmed with sonography or laparoscopy

    Time frame: 7 weeks

  4. Miscarriage rate, defined as the loss of a pregnancy prior to 12 weeks gestation

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Nov 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2016
First posted
Dec 8, 2016
Start
Dec 2016
Primary completionEst.
Nov 2017
CompletionEst.
Dec 2017
Last update
Jul 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02987075
Lead sponsor
Vietnam National University
Responsible party
Manh Tuong Ho (Director, Vietnam National University) — Principal investigator
First posted
Dec 8, 2016
Start date
Dec 2016
Primary completion
Nov 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Jul 17, 2017

Study contacts

Tuong M Ho, MD
Contact
homanhtuong@yahoo.com
+84 906633377
Anh H Dang, Msc
Contact
anh.dh@myduchospital.vn
+ 84 908 302412
Tuong M Ho, MD
principal investigator · CGRH - Vietnam National University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion